A US?based KOL discusses the acute lymphoblastic leukemia (ALL) treatment landscape, highlighting patient stratification by age and Ph status and evolving management across frontline and relapsed settings. The discussion covers use of TKIs, blinatumomab, inotuzumab, CAR?T therapies and stem cell transplantation, alongside perspectives on shifting treatment sequencing, reduced reliance on intensive chemotherapy, and key unmet needs in duration and tolerability of therapy.

This interview was conducted on July 18, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.